

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/824,527	04/15/2004	Bum-Joon Kim	5823.0260-00	7151
22852 7590 04/16/2008 FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER			EXAMINER	
LLP 901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413			SITTON, JEHANNE SOUAYA	
			ART UNIT	PAPER NUMBER
			1634	
			MAIL DATE	DELIVERY MODE
			04/16/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Examiner-Initiated Interview Summary	10/824,527	KIM ET AL.				
Examiner-initiated interview Summary	Examiner	Art Unit				
	Jehanne S. Sitton	1634				
All Participants: Status of Application: Non-final rejection						
(1) <u>Jehanne S. Sitton</u> .	(3)					
(2) Rebecca McNeill.	(4)	(4)				
Date of Interview: 7 April 2008	Time:					
Type of Interview:  ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)  Exhibit Shown or Demonstrated: ☐ Yes If Yes, provide a brief description:						
Part I. Rejection(s) discussed: NA Claims discussed: 6-8, 13						
Prior art documents discussed: NA						
Part II. SUBSTANCE OF INTERVIEW DESCRIBING THE GENE See Continuation Sheet	ERAL NATURE OF WHAT WAS	S DISCUSSED:				
Part III.  ☑ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.						
/Jehanne S Sitton/ Primary Examiner, Art Unit 1634	Applicant/Applicant's Representat	ive Signature – if appropriate)				

Application No. 10/824,527

Continuation of Substance of Interview including description of the general nature of what was discussed: The examiner indicated that the method claims would be rejoined and suggested using the traditional Maxim recitation "selected from the group consisting of" in claims 6, 7, 8. Additionally, the examiner indicated that a number of SEQ ID NOS were identical to each other. They are: 43 and 45; 46 and 34; 47 and 48; and 51-54. The examiner indicated that one of each of the duplicate SEQ ID NOS should be deleted from the claims. It was aknowledged that the duplication arose from the different strains which were isolated and sequenced and indicated in the seugence listing. However, the examiner pointed out the the SEQ ID NO was only a representation of a particular nucleotide sequence, not to other information in the sequence listing, and that deletion of duplicative SEQ ID NOS did not alter the scope of the claims. Applicant's attorney agreed to the changes in the attached Examiner's amendment.